2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B1615
    Clenbuterol 37148-27-9 98%
    Clenbuterol (NAB-365) is a β2-adrenergic receptor agonist with an EC50 of 31.9 nM. Clenbuterol is a very potent inhibitor of the lipopolysaccharide (LPS)-induced release of TNF-α and IL-1β. Clenbuterol can inhibit the inflammatory process. Clenbuterol is a bronchodilator.
    Clenbuterol
  • HY-B1831
    Oritavancin 171099-57-3 98%
    Oritavancin (LY 333328), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity.
    Oritavancin
  • HY-P3449
    Dazdotuftide 2522933-44-2 98%
    Dazdotuftide (TRS01) is an active compound and can be used as an immunomodulator.
    Dazdotuftide
  • HY-P3494
    Hepcidin-25 (human) 1356390-47-0 98%
    Hepcidin-25 (human) is an iron metabolism regulator and Antimicrobial agent. Hepcidin-25 (human) exerts anti-inflammatory and antimicrobial activities by regulating iron-mediated oxidative damage.
    Hepcidin-25 (human)
  • HY-100864
    mPGES1-IN-3 1469976-70-2 98%
    mPGES1-IN-3 (Compound 17d) is a potent and selective microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor, which exhibits excellent mPGES-1 enzyme (IC50: 8 nM), cell (A549 IC50: 16.24 nM) and human whole blood potency (IC50: 249.9 nM).
    mPGES1-IN-3
  • HY-102036
    G-744 1346669-54-2 98%
    G-744 is a highly potent, selective and orally active Btk inhibitor with an IC50 of 2 nM. G-744 is metabolically stable, well tolerated and efficacious to treat arthritis.
    G-744
  • HY-102085
    11-Deoxyglycyrrhetinic acid sodium 1148013-87-9 98%
    11-Deoxyglycyrrhetinic acid sodium is a compound that exhibits anti-inflammatory activity. 11-Deoxyglycyrrhetinic acid sodium activates the Ca2+/voltage-gated K+ large conductance (BK) (cbv1 + β1) channels cloned from rat cerebral artery myocytes with the EC50 of 53 μM.
    11-Deoxyglycyrrhetinic acid sodium
  • HY-108661
    NF546 1006028-37-0 98%
    NF546 is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
    NF546
  • HY-109094
    Mosedipimod 221139-79-3 98%
    Mosedipimod is a monoacetyldiaglyceride that can be isolated from Cervus nippon Temminck. Mosedipimod is an orally active Toll-Like Receptor signaling inhibitor. Mosedipimod attenuates airway infammation by reducing myeloperoxidase expression in lung tissue. Mosedipimod is used in chronic obstructive pulmonary disease research.
    Mosedipimod
  • HY-109175
    Fosifidancitinib 1237168-58-9 98%
    Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases.
    Fosifidancitinib
  • HY-111165
    SNX-7081 908111-22-8 98%
    SNX-7081 is an Hsp90 inhibitor with Ki and IC50 values of 26 nM and 44 nM, respectively. SNX-7081 blocks the nuclear translocation of NF-κB, inhibits the production of pro-inflammatory cytokines, attenuates the ERK/JNK and PDGF signaling pathways, and suppresses LPS (HY-D1056)-induced nitric oxide production. SNX-7081 inhibits DNA repair, induces G2/M cell cycle arrest, and triggers apoptosis via downregulation of MYC/nucleolin and activation of Fas. SNX-7081 can be used in research related to rheumatoid arthritis and cancer.
    SNX-7081
  • HY-111509
    TAK-828F 1854901-94-2 98%
    TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC50=1.9 nM, reporter gene IC50=6.1 nM). TAK-828F shows excellent RORγt isoforms selectivity (>5000-fold selectivity against human RORα and RORβ).
    TAK-828F
  • HY-111748
    RORγt Inverse agonist 2 1801197-92-1 98%
    RORγt Inverse agonist 2 is a selective, orally active RORγt inverse agonist with an EC50 of 119 nM.
    RORγt Inverse agonist 2
  • HY-112286
    PI3Kγ inhibitor 2 1315538-79-4 98%
    PI3Kγ inhibitor 2 (Compound 16) is an orally bioavailable, CNS-penetrant, isoform selective PI3Kγ inhibitor with a Ki of 4 nM.
    PI3Kγ inhibitor 2
  • HY-112439
    PI3Kdelta inhibitor 1 2242109-74-4 98%
    PI3Kdelta inhibitor 1 (Compound 5d) is a potent, selective and orally available PI3Kδ inhibitor with an IC50 of 1.3 nM.
    PI3Kdelta inhibitor 1
  • HY-112604
    MK-8318 1416581-40-2 98%
    MK-8318 is a potent and selective CRTh2 receptor antagonist with a Ki of 5.0 nM.
    MK-8318
  • HY-114038
    SB-747651A 607372-46-3 98%
    SB-747651A is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC50 of 11 nM. SB-747651A also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A can be used for inflammation research.
    SB-747651A
  • HY-114147
    Tuberculosis inhibitor 3 2219325-28-5 98.50%
    Tuberculosis inhibitor 3 (compound 2i) displays potent anti-TB activity (MIC < 0.016 μg/mL) against agent-sensitive/resistant MTB strains. Tuberculosis inhibitor 3 (compound 2i) shows acceptable PK profiles with oral bioavailability.
    Tuberculosis inhibitor 3
  • HY-114193
    CCR1 antagonist 6 2436773-01-0 98%
    CCR1 antagonist 6 (compound 16q) is a chemokine receptor 1 (CCR1) antagonist, with an IC50 of 3 nM.
    CCR1 antagonist 6
  • HY-114194
    CCR1 antagonist 7 2446154-74-9 98%
    CCR1 antagonist 7 (compound 16r) is a chemokine receptor 1 (CCR1) antagonist, with an IC50 of 4 nM.
    CCR1 antagonist 7
Cat. No. Product Name / Synonyms Application Reactivity